Anavex Life Sciences (AVXL) Scheduled to Post Quarterly Earnings on Thursday

Anavex Life Sciences (NASDAQ:AVXL) will be announcing its earnings results before the market opens on Thursday, May 9th. Analysts expect the company to announce earnings of ($0.13) per share for the quarter. Investors interested in listening to the company’s conference call can do so using this link.

Anavex Life Sciences (NASDAQ:AVXL) last announced its quarterly earnings data on Wednesday, February 7th. The biotechnology company reported ($0.11) EPS for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.04. On average, analysts expect Anavex Life Sciences to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Anavex Life Sciences Stock Performance

Shares of NASDAQ:AVXL opened at $3.84 on Wednesday. Anavex Life Sciences has a one year low of $3.25 and a one year high of $10.45. The stock has a fifty day moving average of $4.51 and a 200-day moving average of $5.89. The company has a market capitalization of $315.30 million, a PE ratio of -7.11 and a beta of 0.66.

Insider Activity

In other news, CEO Christopher U. Missling sold 73,380 shares of the stock in a transaction on Thursday, March 28th. The stock was sold at an average price of $5.11, for a total transaction of $374,971.80. Following the completion of the sale, the chief executive officer now owns 1,250,210 shares in the company, valued at approximately $6,388,573.10. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 11.60% of the company’s stock.

Anavex Life Sciences Company Profile

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.